Diagnosing NMOSD: Antibody Testing and the Expansion of the Neuromyelitis Optica Spectrum Disorder Market
Accurate diagnosis is the foundation of effective treatment — and in neuromyelitis optica spectrum disorder, diagnosis has been transformed by antibody testing. The discovery of aquaporin-4 antibodies revolutionised understanding of the disease, distinguishing it from multiple sclerosis and enabling targeted therapy. This diagnostic advance is a major factor expanding the NMOSD market, as...
0 Комментарии 0 Поделились 90 Просмотры 0 предпросмотр